ClinicalTrials.Veeva

Menu

Sustainable Healthcenter Implementation PrEP Pilot Study (SHIPP)

Centers for Disease Control and Prevention (CDC) logo

Centers for Disease Control and Prevention (CDC)

Status

Completed

Conditions

HIV Preexposure Prophylaxis
HIV Chemoprophylaxis

Treatments

Drug: coformulated TDF/FTC

Study type

Observational

Funder types

Other
Other U.S. Federal agency
Industry

Identifiers

NCT02074891
CDC-NCHHSTP-6511

Details and patient eligibility

About

A health services implementation pilot study, conducted with an observational cohort of HIV-uninfected persons including men who have sex with men, heterosexual women and men, and injection drug users receiving daily oral antiretroviral preexposure prophylaxis (PrEP) at four federally qualified health centers that provide sexual health and primary care services to communities with high HIV incidence/prevalence.

Enrollment

1,420 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • adult
  • documented without HIV infection (acute or established)
  • report sexual behaviors that indicate substantial risk of HIV acquisition
  • report injection-related behaviors that indicate substantial risk of HIV acquisition

Exclusion criteria

  • <18 years of age
  • documented HIV infection (acute or established)

Trial design

1,420 participants in 1 patient group

Persons prescribed PrEP
Description:
adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
Treatment:
Drug: coformulated TDF/FTC

Trial contacts and locations

5

Loading...

Central trial contact

Dawn K Smith, MD, MS, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems